| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Centessa Pharmaceuticals plc$40.5
+0.47 (+1.17%)
D 35Pipeline Score Overvalued Pharma · Commercial
Market Cap
6.15 B
EPS
-1.77
P/E Ratio
-
Value Trade
33.49 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
-
R&D Expenses
59.89 M
Operating CF
-72.22 M
Total Assets
641.76 M
Total Liabilities
154.41 M
Equity
487.35 M
D/E Ratio
12,345
0.38 %
Week
0.56 %
1 Month
59.32 %
3 Month
43.35 %
6 Month
96.3 %
5 Year
96.3 %
All Time
Cash Data
Cash Position
276.59 M
Monthly Burn
24.07 M
Runway
10.1 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
11.33 M
52 Week Range
10.95 - 40.26
% held by Insiders
29.35 %
% held by Institutions
70.86 %
Enterprise Value
5.99 B
Total Shares
154.73 M
Short %
2.35 %
Float Shares
109.31 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $515M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.3x
rNPV / MCap Top 48%
Small Cap (rank 472 of 905)
Percentile RankCentessa Pharmaceuticals plc faces pipeline headwinds (35/100), with $1.1B risk-adjusted pipeline value, led by SerpinPC in Hemophilia a (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SerpinPC Small molecule | Hemophilia a | Phase 1 | NCT04073498 | 46% | $787M | COMPLETED | 39 | - | - | Sep 26, 2024 | - | Feb 6, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ORX750 | narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia | Phase 2a | 2025-08-12 | |||
ORX750 | narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia | Phase 2a | 2025-08-12 | |||
ORX750 | narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia | Phase 2a | 2025-08-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CNTA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CNTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNTAAcquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38.00 per share, plus contingent value rights. The total transaction value is approximately $7.8 billion. The acquisition is expected to close on June 24, 2026, pending regulatory approvals. Centessa aims to develop innovative therapies for neurological conditions.
Read more →CNTACentessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals announced its participation in several upcoming investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit and the TD Cowen 46th Annual Health Care Conference. These events will feature fireside chats with the management team, providing insights into the company's innovative approaches in developing therapies for various disorders. Live webcasts and recordings will be accessible on their investor relations website.
Read more →CNTACentessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Centessa Pharmaceuticals announced new preclinical data at the ACNP Annual Meeting, demonstrating that activation of the Orexin Receptor 2 (OX2R) can reduce behavioral despair and enhance wakefulness in an animal model of major depressive disorder. This supports the potential of OX2R agonists for rapid-onset treatment of mood symptoms and excessive daytime sleepiness. The findings may lead to the expansion of their OX2R pipeline into additional neuropsychiatric indications.
Read more →CNTAUK EMPLOYMENT AGREEMENT This Employment Agreement (this " Agreement ") is made by and between Centessa Pharmaceuticals (UK) Limited (referred to herein as the " Company ") and Mario Alberto Accardi (the " Executive ") on
Centessa Pharmaceuticals has established a new employment agreement with Mario Alberto Accardi, effective January 1, 2026. Accardi will continue as the Chief Executive Officer under revised terms that include an annual salary of $600,000 and eligibility for performance-based bonuses. The agreement outlines specific responsibilities and compliance requirements for the Executive, including adherence to relevant regulatory standards. Additionally, both parties must provide a six months' notice for termination.
Read more →CNTACentessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals has announced the appointment of Dr. Mario Alberto Accardi as CEO, effective January 1, 2026, succeeding Dr. Saurabh Saha. This leadership change reflects the company's strategic shift towards a focused orexin portfolio, with plans to advance multiple neuroscience indications. Dr. Accardi aims to leverage his expertise to enhance Centessa's pipeline and capitalize on growth opportunities in neuroscience.
Read more →CNTACentessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals has announced the pricing of a public offering of 11,627,907 American Depositary Shares at $21.50 each, aiming to raise approximately $250 million. The offering is set to close around November 14, 2025, subject to customary conditions. The company is also granting underwriters an option to purchase additional shares.
Read more →CNTACentessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals has announced a proposed public offering of American Depositary Shares (ADSs), each representing one ordinary share. The offering is underwritten and includes a potential 30-day option for underwriters to purchase additional shares. The offering's completion is contingent on market conditions and other factors.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Centessa Pharmaceuticals reported positive Phase 2a data for ORX750, an OX2R agonist, indicating significant improvements in wakefulness for narcolepsy patients. The drug demonstrated a favorable safety profile and is expected to enter a registrational program in Q1 2026. Additionally, ORX142's Phase 1 data showed promising results in healthy volunteers, with plans for further patient studies.
Read more →CNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Centessa Pharmaceuticals will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9th. The management team will engage in a fireside chat to discuss the company's innovative therapies, particularly in the area of orexin receptor 2 agonists. A live audio webcast will be available for those interested in the event.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Centessa Pharmaceuticals reported its financial results for Q2 2025, highlighting advancements in its orexin receptor 2 (OX2R) agonist pipeline. The company is focused on its lead candidate, ORX750, which is in an adaptive Phase 2a study aimed at treating sleep-wake disorders. Upcoming data readouts for ORX750 and ORX142 are anticipated this year, reinforcing Centessa's position in the orexin space.
Read more →CNTACentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Centessa Pharmaceuticals has received FDA clearance for an IND to initiate a Phase 1 clinical study of ORX142, a novel OX2R agonist. This study will assess the safety and pharmacokinetics of ORX142 in healthy volunteers, with results expected later this year. The drug aims to address unmet needs in neurological and neurodegenerative disorders.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Centessa Pharmaceuticals reported its financial results and business highlights for Q1 2025, showcasing progress in its OX2R agonist pipeline. The ORX750 Phase 2a CRYSTAL-1 study is expected to yield data for narcolepsy type 1, type 2, and idiopathic hypersomnia this year, indicating strong potential for first-in-class therapies. Additionally, the company is preparing to initiate first-in-human studies for ORX142, targeting various neurological and neurodegenerative disorders. Financially, Centessa ended the quarter with approximately $424.9 million, supporting its clinical endeavors well into 2027.
Read more →CNTACentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Centessa Pharmaceuticals reported its business highlights and financial results for the fourth quarter and full-year 2024, showcasing promising developments in its OX2R agonist pipeline, particularly ORX750, which is progressing in the Phase 2a CRYSTAL-1 study for narcolepsy indications. Data from a Phase 1 study indicates ORX750 effectively increases wakefulness in sleep-deprived volunteers. However, the company faces challenges, evident in a significant net loss attributed to clinical program discontinuations. Overall, Centessa is well-positioned with substantial cash reserves to fund ongoing and future studies.
Read more →CNTACentessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
Centessa Pharmaceuticals has revealed plans to present Phase 1 clinical trial data for its investigational orexin receptor 2 agonist, ORX750, at the upcoming American Academy of Neurology 2025 Annual Meeting. This treatment aims to address sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. The presentation is scheduled for April 5, 2025, and will feature insights from a study conducted with sleep-deprived healthy participants. The company is optimistic about the drug's potential as it continues to progress into Phase 2a trials.
Read more →CNTACentessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
Centessa Pharmaceuticals has announced the appointment of Dr. Stephen Kanes as Chief Medical Officer. With over 30 years of experience in neuroscience and clinical psychiatry, Dr. Kanes is expected to enhance the company's abilities in advancing its orexin receptor 2 (OX2R) agonists. The company is currently progressing in its clinical trials for these medications, particularly ORX750, aimed at treating various sleep and psychiatric disorders. His prior experience at Sage Therapeutics positions him well to contribute to Centessa's growth in innovative therapeutic areas.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals (CNTA) reported its financial results for Q3 2024 alongside significant updates on its clinical programs. The company shared promising interim data for ORX750, demonstrating potential as a best-in-class treatment for narcolepsy and idiopathic hypersomnia. A Phase 2a clinical study for ORX750 has been initiated, with data expected in 2025. To focus on its OX2R agonist programs, Centessa has made a strategic decision to discontinue the development of SerpinPC.
Read more →CNTACentessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals presented preclinical data for ORX142, a novel orexin receptor 2 agonist, at the Sleep Europe 2024 conference. The data from non-human primate studies demonstrate ORX142's potential in treating excessive daytime sleepiness associated with various neurological and psychiatric disorders. The compound showed significant efficacy in promoting wakefulness even at low doses and is being rapidly advanced through IND-enabling studies. This represents a promising addition to Centessa's growing pipeline of OX2R agonists.
Read more →CNTACentessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals announced the pricing of an upsized public offering of 15,254,237 American Depositary Shares at $14.75 per ADS, aiming to raise roughly $225 million. The offering is set to close around September 16, 2024. Further, underwriters are provided a 30-day option to purchase additional shares, reflecting confidence in demand. The company focuses on developing transformative medicines, including programs for hemophilia and narcolepsy.
Read more →CNTACentessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals has announced a proposed public offering of $150 million of American Depositary Shares (ADSs), representing ordinary shares of the company. The offering includes a 30-day option for underwriters to purchase an additional $22.5 million in ADSs. While the company aims to enhance its capital for developing transformative medicines, the offering is subject to market conditions, and there are no guarantees regarding its completion or the exact terms. The announcement underscores a strategic financial move while highlighting potential risks involved.
Read more →CNTACentessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers 2.5 mg dose restored normative wakefulness with mean sleep l
Centessa Pharmaceuticals announced positive interim data from its Phase 1 clinical trial of ORX750, an orexin receptor 2 agonist, in acutely sleep-deprived healthy volunteers. The trial showed significant improvements in sleep latency at doses of 1.0 mg and 2.5 mg, specifically highlighting a 32-minute mean sleep latency restoration with the 2.5 mg dose. The company plans to advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, type 2, and idiopathic hypersomnia beginning in the fourth quarter of 2024, capitalizing on the favorable safety and tolerability profile observed in the interim results.
Read more →CNTACentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Centessa Pharmaceuticals has announced the acceptance of preclinical data for ORX142, an orexin receptor 2 (OX2R) agonist, for a late-breaking poster presentation at the 27th Congress of the European Sleep Research Society in September 2024. The data shows that low doses of ORX142 promoted wakefulness in non-human primates, indicating its potential in treating excessive daytime sleepiness associated with various neurological disorders. This marks the second drug candidate from Centessa's pipeline aimed at improving sleep-wake disorders, demonstrating significant therapeutic promise. Details about the presentation, including poster number and schedule, were also shared.
Read more →CNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Centessa Pharmaceuticals announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference to be held in New York City. Members of the management team will engage in a fireside chat on September 4th at 1:05 PM ET. The event aims to showcase the company's commitment to discovering and developing innovative treatments, including programs for hemophilia, narcolepsy, and immuno-oncology. The event will be accessible via live audio webcast on the company's investor relations page.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa Pharmaceuticals has reported its financial results and business highlights for Q2 2024. The company is making progress with its orexin receptor 2 (OX2R) agonist program, having initiated a Phase 1 clinical study for ORX750 targeting sleep-wake disorders. Additionally, they nominated ORX142 for development aimed at neurological and psychiatric conditions associated with excessive daytime sleepiness. Despite a significant net loss reported for the quarter, Centessa maintains a robust cash position sufficient to support operations through mid-2026.
Read more →CNTACentessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer | Source: Centessa Pharmaceuticals plc Sha
Centessa Pharmaceuticals announced the appointment of John Crowley CPA as Chief Financial Officer and Gregory Weinhoff MD MBA as Chief Business Officer, effective June 10, 2024. This leadership transition comes as the company looks to strengthen its operational and strategic capabilities, with all three core programs currently in the clinic. Crowley brings over 20 years of experience in finance within the life sciences sector, while Weinhoff will leverage his extensive background in business development. Such enhancements aim to empower Centessa's mission to deliver transformative medicines to patients.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals has reported promising business highlights for Q1 2024, including the initiation of the Phase 1 trial for ORX750, a novel treatment for narcolepsy. The company's ongoing studies for SerpinPC in hemophilia B are advancing, with an interim analysis of the PRESent-2 study expected this year. Centessa's financial performance shows improvement, with a significant increase in cash reserves following a recent public offering. The CEO remains optimistic about the potential of their clinical programs to address significant unmet medical needs in several therapeutic areas.
Read more →CNTACentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
Centessa Pharmaceuticals plc has announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (ADSs) at $9.25 per ADS, with expected gross proceeds of approximately $100 million. The offering is set to close on April 26, 2024, or around that date, and underwriters have a 30-day option to purchase additional ADSs. Goldman Sachs and several other firms are managing the offering, which follows the registration statement that was previously filed with the SEC.
Read more →CNTACentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals has announced a proposed public offering of $100 million of American Depositary Shares, with plans to grant underwriters an option for an additional $15 million. The offering's completion is subject to market conditions and other factors, creating uncertainty about the actual terms. Major firms like Goldman Sachs and Leerink Partners are leading the offering, which reflects investor interest and potential growth for the company. The offering aims to support the development of transformative medicines.
Read more →CNTACentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
Centessa Pharmaceuticals announced that the FDA has cleared their Investigational New Drug application for ORX750, an orexin receptor agonist aimed at treating narcolepsy. A Phase 1 clinical trial will evaluate the drug’s safety and pharmacokinetics in healthy adult subjects, with proof-of-concept data expected by the second half of 2024. ORX750 is positioned to address narcolepsy type 1 and type 2, as well as other sleep-wake disorders. This milestone is considered significant in Centessa's ongoing drug development efforts.
Read more →CNTACentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Centessa Pharmaceuticals has reported business highlights and financial results for Q4 and the full year 2023. Key developments include ongoing studies of SerpinPC for hemophilia B, with significant efficacy shown in reducing bleeding rates. The company is also advancing its orexin receptor 2 agonist, ORX750, and initiating a first-in-human study of its LockBody technology platform with LB101. Financial results showed a net loss decrease compare to the previous year, with sufficient cash reserves for future operations.
Read more →CNTACentessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
Centessa Pharmaceuticals plc announced its participation in TD Cowen’s 44th Annual Health Care Conference in Boston, scheduled for March 5th. The management team will engage in a fireside chat, providing insights into the company's ongoing projects and pipeline. The event aims to increase visibility and foster interaction with potential investors. Centessa focuses on developing innovative treatments, including programs for hemophilia and narcolepsy.
Read more →CNTACentessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Centessa Pharmaceuticals announced the presentation of an additional 52 weeks of treatment data for SerpinPC, a novel inhibitor aimed at treating hemophilia, during the 17th Annual Congress of the EAHAD. The data, presented in Frankfurt on February 9, 2024, showcases the ongoing Phase 2a study's results, reinforcing confidence in SerpinPC's potential as a convenient treatment option. SerpinPC has received Fast Track designation from the FDA, marking it as a significant development in hemophilia treatment options.
Read more →CNTACentessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
Centessa Pharmaceuticals announced new long-term data for SerpinPC, an investigational treatment for hemophilia, during the ASH Annual Meeting. The latest findings from the ongoing Phase 2a study showed a significant 96% reduction in median all-bleed annualized bleeding rate (ABR) with no observed adverse events. This data reinforces the favorable safety profile of SerpinPC and enhances its potential as a convenient therapy for hemophilia patients. The company is proceeding with additional registrational studies for this innovative treatment.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
Centessa Pharmaceuticals reported its financial results and business highlights for Q3 2023, showcasing ongoing registrational studies for SerpinPC in hemophilia B. The company is set to present new data at the ASH Annual Meeting and is advancing its ORX750 program, which may position it as a leading treatment for narcolepsy. Additionally, Centessa's LockBody technology continues in clinical trials, and the company's financial health appears robust, with cash expected to support operations into 2026. However, the company still faces net losses despite cost reductions in R&D efforts.
Read more →CNTACentessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
Centessa Pharmaceuticals announced that it will present new data from an additional 52 weeks of continuous treatment in its ongoing Phase 2a study of SerpinPC, a novel treatment for hemophilia, during the upcoming ASH Annual Meeting on December 10, 2023. The study, which examines the safety and efficacy of the drug, is crucial as it aims to provide further insights into the treatment of hemophilia B. SerpinPC has already received Fast Track designation from the FDA for its development, indicating its potential significance in this therapeutic area.
Read more →CNTACentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
Centessa Pharmaceuticals has initiated dosing for the first subject in its REGISTRATIONAL PRESent-3 study, focused on SerpinPC for hemophilia B with inhibitors. This investigational treatment was previously granted Fast Track designation by the FDA. The study aims to assess the efficacy and safety of SerpinPC, expanding the options for individuals with limited treatment choices. While the company is optimistic about the novel mechanism of action, there are inherent risks associated with the approval process and recruitment for clinical trials.
Read more →CNTACentessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders Preclinical data demonstrated signific
Centessa Pharmaceuticals has announced promising preclinical data for its investigational drug ORX750, a novel oral orexin receptor 2 (OX2R) agonist, which demonstrated significant activity in treating narcolepsy and other sleep-wake disorders. Low doses of ORX750 were effective in enhancing wakefulness and suppressing cataplexy in mouse models representative of narcolepsy type 1. The company is advancing ORX750 through IND-enabling studies and plans to release clinical proof of concept data in 2024. This positions ORX750 as a potential best-in-class treatment in its category.
Read more →CNTACentessa Pharmaceuticals Announces Additions to Senior Leadership Team
Centessa Pharmaceuticals has announced the addition of two new senior leaders: April Dovholuk, Senior VP of Development Operations, and Dr. Ellie Im, Senior VP of Clinical Development in Oncology. These appointments are aimed at enhancing the company's capabilities in managing clinical trials and advancing its oncology programs, including SerpinPC for hemophilia B and LB101 for solid tumors. The leadership change comes at a strategic time as the company aims to drive its portfolio of clinical trials forward, with both individuals bringing significant industry experience.
Read more →CNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Centessa Pharmaceuticals plc will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023. Members of its management team are expected to take part in a fireside chat at 4:15 p.m. ET. The event will be accessible via a live webcast and recorded for later viewing. This participation underscores Centessa's commitment to engaging with stakeholders and promoting their development in rare diseases and immuno-oncology.
Read more →CNTACentessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
Centessa Pharmaceuticals announced it will present preclinical data for ORX750, its first orexin receptor 2 (OX2R) agonist, at the World Sleep Congress from October 20-25, 2023, in Rio de Janeiro, Brazil. This orally administered drug is under development for treating narcolepsy and other sleep disorders. The company's CEO, Saurabh Saha, expressed high hopes for ORX750 as a potential best-in-class treatment. Additionally, Dr. Sarah Wurts Black will co-chair a symposium on orexin receptor agonists at the conference.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
Centessa Pharmaceuticals has reported positive advancements in its clinical pipeline and financial results for Q2 2023. The company is actively enrolling patients in the registrational study for SerpinPC, aimed at treating hemophilia B. Additionally, progress is being made with its LockBody technology platform, which includes two new bispecific monoclonal antibodies. Financially, Centessa has sufficient cash reserves to support operations through 2026, indicating a stable outlook for the company's development activities.
Read more →CNTACentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-2 study, evaluating SerpinPC for treating hemophilia B without inhibitors. This investigational therapy is aimed at addressing the significant need for new treatment options in this area. The study is designed to assess the efficacy and safety of SerpinPC through various dosing regimens and is expected to include approximately 120 subjects. The FDA has recognized the potential of SerpinPC by granting it Fast Track designation to expedite its review process.
Read more →CNTACentessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
Centessa Pharmaceuticals has received Fast Track designation from the U.S. FDA for its investigational treatment, SerpinPC, aimed at hemophilia B. This designation acknowledges the drug's potential as a novel therapy with a differentiated safety profile. The company is advancing several clinical studies, including registrational programs, to further evaluate SerpinPC's effectiveness. The Fast Track status allows for expedited development and review processes, potentially leading to quicker access for patients in need.
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clin
Read more →CNTACentessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program t
Read more →CNTACentessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Ce
Read more →CNTACentessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional d
Read more →CNTACentessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team wi
Read more →CNTACentessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody Candidate, for Solid Tumors
BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has received clearance of its Inve
Read more →CNTACentessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93% reduction in median ABR for both all-bleeds and spontaneous joint bleeds in highest d
Read more →CNTACentessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People
Read more →CNTACENTESSA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
NEW ORLEANS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 28, 2022 to file lead plaintiff applications in a securities class action lawsuit against Centessa Pharmaceuticals plc (NasdaqGS: CN
Read more →CNTACENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)
Did you lose money on investments in Centessa Pharmaceuticals? If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -
Read more →CNTACENTESSA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
NEW ORLEANS, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications in a securities class action laws
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous
Read more →CNTACentessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC for the t
Read more →CNTACentessa Pharmaceuticals plc Investors: Please contact the Portnoy Law Firm to recover your losses; Last days to actively participate in the case; November 28, 2022
LOS ANGELES, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) that a class action has been filed on behalf of investors. Centessa investors that lost money on their investment are encouraged t
Read more →CNTACentessa Pharmaceuticals plc (CNTA) Class Action Notice: If You Incurred Significant Losses in Centessa Pharmaceuticals plc Contact Robbins LLP for Information About Your Rights
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ: CNTA) American Depository Shares (
Read more →CNTACentessa Pharmaceuticals plc Equity Notice: Centessa Pharmaceuticals plc (CNTA) Shareholders with Significant Losses Should Contact Robbins LLP for Information About their Rights
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ: CNTA) American Depository Shares (
Read more →CNTACentessa Pharmaceuticals plc Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Centessa Pharmaceuticals plc (CNTA)
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ: CNTA) American Depository Shares (
Read more →CNTACENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)
Did you lose money on investments in Centessa Pharmaceuticals? If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE)
Read more →CNTACentessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA
Read more →CNTACentessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 - BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with
Read more →CNTACentessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
BOSTON and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patient
Read more →CNTACentessa Pharmaceutical plc Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 11, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Centessa Pharmaceutical plc (“”CNTA” or the “Company”) (NASDAQ: CNTA) investors that the firm has initiated an in
Read more →CNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two y
Read more →CNTACentessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, t
Read more →CNTACentessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients,
Read more →CNTACentessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody Program at 2022 ASCO Annual Meeting
BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients,
Read more →CNTACentessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to significantly reduce cash burn and extend cash runway into 2026 - - Company continu
Read more →CNTACentessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates - Company advances innovative rare disease and immuno-oncology portfolio toward 4x24' goal of four registrational progra
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates - Company advances innovative rare disease and immuno-oncology portfolio toward 4x24' goal of four registrational programs in 2024 - - Poster presentation at ASCO 2022 to highlig
Read more →CNTACentessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on Hemophilia B with and without inhibitor
Read more →CNTACentessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am East
Read more →CNTACentessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today an
Read more →CNTACentessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial
Read more →CNTADocument Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease BOSTON and LONDON
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease BOSTON and LONDON, February 24, 2022 - Centessa Pharmaceuticals plc (Nasdaq CNTA) (the "Company"), together with its subsidiary Palladio Bio
Read more →CNTADocument Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowa
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application Initiation of registr
Read more →CNTACentessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the ALERT Study who previously discontinued JYNARQUE® due to liver toxicity successfully
Read more →CNTACentessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announc
Read more →CNTACentessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds i
Read more →CNTACentessa Pharmaceuticals to Present at Upcoming Conferences in 2021
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the following investor conferences: Event: Jefferies London Healthcare Conference Da
Read more →CNTACentessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874 First demonstration that a pharmacological chaperone can provide sufficient functi
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874 First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 1
Read more →CNTACentessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
BOSTON and LONDON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announc
Read more →CNTADocument Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital New $300 million facility, combined with Company's cash balance as of
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic bus
Read more →CNTACentessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
BOSTON and LONDON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa” or “Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients,
Read more →CNTACentessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ~ Confe
Read more →CNTACentessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Hea
Read more →CNTACentessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates
~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~ ~ Centessa leadership team strengthened through appointment of key industry executives
Read more →CNTACentessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare
Read more →CNTACentessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today th
Read more →Competitive Position
How CNTA ranks across every disease it competes inCompetitive Position is a premium feature
See how CNTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial